Immediate Impact
27 standout
Citing Papers
The present and future of bispecific antibodies for cancer therapy
2024 Standout
Indolent CD4+ CAR T-Cell Lymphoma after Cilta-cel CAR T-Cell Therapy
2024 Standout
Works of Levanto Schachter being referenced
Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas
2022
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Levanto Schachter | 109 | 41 | 5 | 95 | 65 | 13 | 226 | |
| Caroline Nickner | 97 | 9 | 6 | 102 | 46 | 11 | 229 | |
| Ulrike Höller | 116 | 59 | 6 | 57 | 39 | 21 | 266 | |
| G. Kessell | 49 | 11 | 8 | 102 | 12 | 8 | 256 | |
| Guangqi Qin | 27 | 11 | 1 | 154 | 31 | 17 | 238 | |
| Jinyi Lin | 68 | 6 | 71 | 67 | 108 | 15 | 293 | |
| Perrine Devic | 102 | 29 | 28 | 26 | 5 | 16 | 270 | |
| Jun Li | 114 | 10 | 1 | 24 | 17 | 13 | 205 | |
| Lars Frich | 42 | 11 | 1 | 53 | 6 | 20 | 288 | |
| Paul Critchley | 37 | 3 | 5 | 90 | 33 | 12 | 278 | |
| Theodore E. Yaeger | 62 | 4 | 60 | 37 | 46 | 10 | 240 |
All Works
Login with ORCID to disown or claim papers
Loading papers...